nference
nference, Inc. is a biotechnology company that offers an AI-based software platform designed to synthesize fragmented biomedical knowledge from various sources, including biomedical literature, molecular data, and real-world datasets. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference provides advanced neural network models for the automated extraction of insights from scientific, clinical, regulatory, and commercial datasets. The company focuses on facilitating drug discovery, life cycle management, and precision medicine, enabling healthcare professionals and biopharmaceutical companies to develop personalized diagnostics and treatments for patients. By transforming electronic medical record data into actionable insights, nference addresses critical challenges in drug discovery and clinical research, enhancing patient care through comprehensive biological and clinical understanding.
Predible Health
Acquisition in 2022
Predible Health Pvt. Ltd. is a Bengaluru-based company that specializes in developing an artificial intelligence platform for cancer radiology. Founded in 2016, the company focuses on aiding radiologists and surgeons in the diagnosis and treatment of cancerous tissues. Its offerings include Predible Liver, which provides autosegmentation for liver imaging, and Predible Lung, which features malignancy scoring, nodule tracking, and response assessment capabilities. Utilizing deep learning technology, Predible Health's platform is trained on millions of CT images to enhance the accuracy and efficiency of cancer diagnosis. The platform is designed to support healthcare professionals in characterizing diseases and planning personalized treatment strategies for patients.
Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.